![PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e7d901374eddb6500e1e3f83e8039d512de691b3/5-Table2-1.png)
PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar
![P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer - Annals of Oncology P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer - Annals of Oncology](https://www.annalsofoncology.org/cms/asset/7b2ec333-e42f-4a7e-9488-8fd8e70c919b/fx1.jpg)
P-121 Phase Ib trial of oxaliplatin, UGT1A1 genotype-directed dosing of irinotecan and chronomodulated capecitabine (OXIRI) chemotherapy in patients with advanced pancreatic cancer - Annals of Oncology
![VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer | 2 Minute Medicine VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2021/01/2MM-VA-1.3.2021_2_Capecitabine_Observation_TNBC-scaled.jpg)
VisualAbstract: Low-dose capecitabine after standard adjuvant therapy improves disease-free survival in patients with early triple-negative breast cancer | 2 Minute Medicine
![PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e7d901374eddb6500e1e3f83e8039d512de691b3/2-Table1-1.png)
PDF] Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer. | Semantic Scholar
![Lower Dose Capecitabine Is Active and Has Favorable Safety Profile in Elderly Patients With Advanced Breast Cancer Lower Dose Capecitabine Is Active and Has Favorable Safety Profile in Elderly Patients With Advanced Breast Cancer](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/abc9c9cb28e5293cdf9a9687c3a5a9f40dfb7897-427x220.gif?fit=crop&auto=format)
Lower Dose Capecitabine Is Active and Has Favorable Safety Profile in Elderly Patients With Advanced Breast Cancer
![Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial | Trials | Full Text Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial | Trials | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13063-015-0753-7/MediaObjects/13063_2015_753_Fig1_HTML.gif)